Congress Materials – Neuroscience Education Institute Congress (NEI 2025)
2025 Neuroscience Education Institute | Nov 6-9 | Colorado Springs, CO
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Adjunctive Lumateperone 42 mg in the Treatment of Major Depressive Disorder: A Pooled Analysis of 2 Phase 3 Randomized Controlled Trials
Willie R. Earley, Suresh Durgam, Susan G. Kozauer, Changzheng Chen, John B. Edwards, Rakesh Jain, Christoph U. Correll
Antipsychotic Utilization, Healthcare Resource Use, Costs, and Quality of Care in Patients with Schizophrenia Enrolled in Medicare, Medicaid, or Both Programs
Pengxiang Li, Zhi Geng, Carmela Benson, Jalpa A Doshi
Change in Clinician-Rated and Patient-Reported Depression Severity After Esketamine Nasal Spray as Monotherapy in Adult Patients With Treatment-Resistant Depression: A Post Hoc Analysis of Item Scores
Richard Shelton, Mai Himedan, Dong-Jing Fu, Ibrahim Turkoz, Amit Patel, Lisa Lim, Oliver Lopena
Efficacy and Safety of Esketamine Nasal Spray as Monotherapy in Adult Patients With Treatment-Resistant Depression for up to 4 Months of Treatment: A Post Hoc Analysis
Andrew J Cutler, Dong-Jing Fu, Ibrahim Turkoz, Mai Himedan, Oliver Lopena, Lisa Lim, John S Verbanac
Long-Term Safety and Efficacy of Esketamine Nasal Spray in Adults With Treatment-Resistant Depression: A Post Hoc Analysis of ESCAPE-LTE
Mai Himedan, Oliver Lopena, Lisa Lim, Ibrahim Turkoz, Ifeanyi Valentine Uche, Yordan Godinov
Long-Term Adjunctive Lumateperone Treatment in Major Depressive Disorder: Results From a Six-Month Open-Label Extension Study
Willie R. Earley, Suresh Durgam, Susan G. Kozauer, Changzheng Chen, Francis Brennan, Andrew J. Cutler
Long-Term Efficacy and Safety of Esketamine Nasal Spray as Monotherapy: A Post Hoc Analysis of the SUSTAIN-3 Study
John Zajecka, Dong-Jing Fu, Ibrahim Turkoz, Patricia Cabrera, Oliver Lopena, Lisa Lim, Megan Kunka Fritz, Muhammad Ahmed
Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder and Anxious Distress
Suresh Durgam, Willie R. Earley, Susan G. Kozauer, Changzheng Chen, Eleni Mastromihalis, Gary S. Sachs
Lumateperone for the Prevention of Relapse in Patients with Schizophrenia: Results From a Double-Blind, Placebo-Controlled, Randomized Withdrawal, Phase 3 Trial
Suresh Durgam, Willie R. Earley, Susan G. Kozauer, Jason Huo, Hassan Lakkis, Christopher Gallardo, Christoph U. Correll
Risk of Relapse with PP1M versus the Most Commonly Utilized OAPs in the US in Adults with Schizophrenia: A Pooled Analysis of PRIDE and PROSIPAL
Nia Josiah, Camilo Obando, Ibrahim Turkoz, Monica Doring, Zachariah Smith, Lisa Lim, Karen Johnston, Martha Sajatovic
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
